ARQT
Arcutis Biotherapeutics Inc.
$26.15
+$0.57(+2.25%)
39
Overall
40
Value
36
Tech
42
Quality
Market Cap
$2.50B
Volume
572.45K
52W Range
$11.13 - $31.77
Target Price
$31.75
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | -- | $3.7M | $29.2M | $166.5M | ||
| Total Revenue | -- | -- | $3.7M | $59.6M | $196.5M | ||
| COST OF GOODS SOLD | |||||||
| Cost of Revenue | -- | -- | $754.0K | $5.0M | $19.1M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | -- | $2.9M | $54.6M | $177.4M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $136.6M | $206.5M | $304.6M | $295.7M | $305.8M | ||
| Research & Development | $115.3M | $145.6M | $182.4M | $110.6M | $76.4M | ||
| Research Expense | $115.3M | $145.6M | $182.4M | $110.6M | $76.4M | ||
| Selling, General & Administrative | $21.3M | $61.0M | $122.1M | $185.1M | $229.4M | ||
| Selling & Marketing Expenses | -- | -- | $1.5M | -- | -- | ||
| General & Administrative Expenses | $21.3M | $61.0M | $122.1M | $185.1M | $229.4M | ||
| Promotion & Advertising | -- | -- | $1.5M | -- | -- | ||
| Salaries & Wages | -- | -- | $32.7M | -- | -- | ||
| Depreciation & Amortization | -- | -- | $622.0K | -- | -- | ||
| Depreciation & Amortization | -- | -- | $622.0K | -- | -- | ||
| Amortization | -- | -- | $312.0K | -- | -- | ||
| Other Operating Expenses | -- | -- | $-3.1M | -- | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-136.6M | $-206.5M | $-301.6M | $-241.1M | $-128.4M | ||
| EBITDA | $-144.4M | $-218.9M | $-306.8M | $-227.4M | $-109.3M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | -- | -- | $15.7M | $29.7M | $27.2M | ||
| Net Non-Operating Interest Income/Expense | -- | -- | $-15.7M | $-29.7M | $-27.2M | ||
| Other Income/Expense | $-967.0K | $-173.0K | $5.8M | $-42.2M | $-46.2M | ||
| Other Special Charges | $967.0K | $173.0K | $5.8M | $42.2M | $46.2M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-144.9M | $-219.8M | $-308.1M | $-229.3M | $-112.2M | ||
| Pre-Tax Income | $-135.7M | $-206.4M | $-311.5M | $-259.0M | $-139.4M | ||
| INCOME TAX | |||||||
| Tax Provision | $-9.2M | $-13.4M | $-12.3M | $3.1M | $647.0K | ||
| NET INCOME | |||||||
| Net Income | $-135.7M | $-206.4M | $-311.5M | $-262.1M | $-140.0M | ||
| Net Income (Continuing Operations) | $-135.7M | $-206.4M | $-311.5M | $-262.1M | $-140.0M | ||
| Net Income (Discontinued Operations) | $-135.7M | $-206.4M | $-311.5M | $-262.1M | $-140.0M | ||
| Net Income (Common Stockholders) | $-135.7M | $-206.4M | $-311.5M | $-262.1M | $-140.0M | ||
| Normalized Income | $-144.9M | $-219.8M | -- | $-204.6M | $-138.0M | ||
| TOTALS | |||||||
| Total Expenses | $136.6M | $206.5M | $305.3M | $300.7M | $324.9M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $35.7M | $49.4M | $55.0M | $69.3M | $121.0M | ||
| Average Shares Outstanding (Diluted) | $35.7M | $49.4M | $55.0M | $69.3M | $121.0M | ||
| Shares Outstanding | $50.1M | $50.4M | $61.1M | $96.8M | $118.6M | ||
| Basic EPS | $-3.8 | $-4.18 | $-5.66 | $-3.78 | $-1.16 | ||
| Basic EPS (Continuing Operations) | $-3.8 | $-4.18 | $-5.66 | $-3.78 | $-1.16 | ||
| Diluted EPS | $-3.8 | $-4.18 | $-5.66 | $-3.78 | $-1.16 | ||
| Diluted EPS (Continuing Operations) | -- | $-4.18 | $-5.66 | $-3.78 | $-1.16 | ||
| OTHER METRICS | |||||||
| Other Gand A | $21.3M | $61.0M | $122.1M | $185.1M | $229.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARQT | $26.15 | +2.2% | 572.45K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arcutis Biotherapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW